Companies / VRTX vs VTRS
VRTX vs VTRS: Vertex Pharmaceuticals and Viatris
Vertex Pharmaceuticals (VRTX) reported $12.0B in revenue against a 32.9% net margin, while Viatris (VTRS) reported $14.3B at a -24.6% net margin, most recently.
| Metric | VRTX | VTRS |
|---|---|---|
| Revenue | $12.0B | $14.3B |
| Net Income | $4.0B | $-3.5B |
| Gross Margin | 86.2% | 35.1% |
| Operating Margin | 34.8% | -18.6% |
| EPS (Diluted) | $15.32 | $-3.00 |
| Free Cash Flow | $3.2B | $1.9B |
| Total Debt | — | $14.4B |
| P/E Ratio | 29.6× | n/m |
| P/B Ratio | 6.2× | n/m |
| Stock Price | $542.69 | $19.00 |
Free: last 5 years
| Fiscal year | FY2018 🔒 | FY2019 🔒 | FY2020 🔒 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|
| VRTX Revenue | ••••• | ••••• | ••••• | $7.6B | $8.9B | $9.9B | $11.0B | $12.0B |
| VTRS Revenue | ••••• | ••••• | ••••• | $17.9B | $16.3B | $15.4B | $14.7B | $14.3B |